A Clinical Study on the Impact of Hemoperfusion on the Prognosis of Uremic Patients Undergoing Maintenance Hemodialysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

162 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2028-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this real-world clinical trial study is to evaluate the impact of hemoperfusion on the prognosis of patients with End-Stage Renal Disease (ESRD) undergoing maintenance hemodialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients

NCT07348913

Regular Low-Frequency Hemoperfusion Medium- to Long-Term Prognosis Maintenance Dialysis Patients +1 more

COMPLETED

Multi-center Clinical Study on Hemoperfusion of KHA80

NCT06233838

Uremia Uremic Osteodystrophy Dialysis Related Complication

RECRUITING NA

Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis

NCT06574425

Chronic Kidney Diseases Hemodialysis

ENROLLING_BY_INVITATION PHASE4

Combination of Hemodialysis With Hemoperfusion：A Clinical Study

NCT02461953

Renal Dialysis Hemoperfusion Quality of Life

COMPLETED NA

Survey and Reduction of Mortality in Peridialysis Uremic Patients Via Intervention of Risk Factors

NCT04088526

End Stage Renal Disease on Dialysis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators are planning to conduct a real-world clinical trial study, enrolling patients with maintenance hemodialysis (MHD) from Huashan Hospital. Patients will be divided into two groups based on their hemoperfusion (HP) treatment frequency: high-frequency HP treatment group (≥1 session every 2 weeks) and low-frequency HP treatment group (\<1 session every 2 weeks). The investigators will collect baseline demographic data, cardiovascular events, cognitive function status, and nutrition-related clinical indicators for both groups. After a 3-year follow-up, The investigators will reassess these parameters to explore the impact of HP on the prognosis of MHD patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

high-frequency hemoperfusion group

≥1 session every 2 weeks

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients undergoing maintenance hemodialysis for ≥3 months Aged ≥18 years and \<85 years; Regular hemodialysis treatment, 3 times per week No residual renal function (urine output \<200 mL/d); Written informed consent has been obtained from the participant.

Exclusion Criteria

Patients with severe cerebrovascular diseases (new-onset cerebral infarction, cerebral hemorrhage) or neurological diseases (autoimmune encephalitis, epilepsy, neurodevelopmental disorders).

Patients with acute severe infections (such as sepsis), severe cardiopulmonary insufficiency (NYHA class IV heart failure, acute exacerbation of COPD), or malignancies.

Patients receiving combined hemodialysis and peritoneal dialysis treatment. Patients with allergic reactions, contraindications, or intolerance to dialysis membrane materials.

Patients with a platelet count \<60 × 10\^9/L. Other conditions deemed by the investigators as unsuitable for participation in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No